Abbott India Annual Analysis - Sustainable Performance Gaining Market Share: Axis Securities
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Axis Securities Report
Abbott India Ltd. outpaced the Indian pharma market revenue growth by 100 basis points in FY21.
This was largely on account of the addition of 15 new products in therapeutic areas such as gastroenterology, central nervous system, metabolics and consumer health.
The company has a leadership position in nine brands out of the top 10 in their respective therapies.
Abbott India’s strategy of going digital and services beyond-the-pill have been key differentiators and game-changers for the company.
Furthermore, its relentless endeavour to move from awareness to compliance to lifestyle modification has resulted in its success over the years.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.